Propel Bio Management
Propel Bio Management reported 29 stocks worth $191M in its 13F filing for Q2 2026, filed Aug 13, 2026. Its largest holdings are PAGP (16.2%), ACHV (13.8%) and CORT (6.2%). Compared with Q1 2026, the fund opened new positions in IMUX, SCYX and SLN, added to ACHV, PHAT and MIST, trimmed CORT, DCTH and CMPS and sold out of VOR, VRDN and OCS.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  PAGP Plains GP Hldgs L P | $30.9M | 16.2% | 1.3M | No change | 8 of 8 | |
| 2 |  ACHV Achieve Life Sciences Inc | $26.3M | 13.8% | 4M | +248K (+7%) | 8 of 8 | |
| 3 |  CORT Corcept Therapeutics Inc | $11.9M | 6.2% | 136K | −11K (−8%) | 2 of 8 | |
| 4 |  PHAT Phathom Pharmaceuticals Inc | $11.4M | 6.0% | 1.1M | +209K (+25%) | 8 of 8 | |
| 5 |  DCTH Delcath Sys Inc | $11M | 5.7% | 871K | −108K (−11%) | 7 of 8 | |
| 6 |  MIST Milestone Pharmaceuticals in | $10M | 5.2% | 7.4M | +3.3M (+80%) | 6 of 8 | |
| 7 |  CMPS Compass Pathways PLC | $8.1M | 4.2% | 573K | −169K (−23%) | 6 of 8 | |
| 8 |  KYTX Kyverna Therapeutics Inc | $7.9M | 4.1% | 883K | +239K (+37%) | 3 of 8 | |
| 9 |  ARTV Artiva Biotherapeutics Inc | $6.8M | 3.5% | 696K | +550K (+376%) | 2 of 8 | |
| 10 |  ABEO Abeona Therapeutics Inc | $6.1M | 3.2% | 983K | −347K (−26%) | 8 of 8 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
 VOR Vor Biopharma Inc Com New | $5.6M | 315K |
 VRDN Viridian Therapeutics Inc | $4.1M | 210K |
 OCS Oculis Holding AG | $3.3M | 122K |
 TRVI Trevi Therapeutics Inc | $2.6M | 224K |
 IMUX Immunic Inc | $2.6M | 2.3M |
🔒 Free account: see all 13.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 13, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Propel Bio Management 13F FAQ
What does Propel Bio Management own?
Propel Bio Management reported 29 stocks worth $191M in its 13F filing for Q2 2026, filed Aug 13, 2026. Its largest holdings are PAGP (16.2%), ACHV (13.8%) and CORT (6.2%). The table above lists every position in the filing (the top 10 without an account).
What did Propel Bio Management buy and sell in Q2 2026?
Compared with Q1 2026: 4 new positions, 11 added to, 10 trimmed and 13 sold out. New positions include IMUX, SCYX and SLN. It sold all of VOR, VRDN and OCS.
When will Propel Bio Management file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Propel Bio Management's portfolio worth?
The Q2 2026 filing reports $191M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.